Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

Video

In Partnership With:

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

The biggest concern 1 year ago was cytokine release syndrome (CRS), says Shah. Although CRS is still commonly seen in approximately 63% of patients, it is relatively well-controlled. Physicians have more experience now—they know when to administer dexamethasone and other agents—and as such, are more comfortable with dealing with it, explains Shah. Concerns over safety have now been replaced with efficacy and durability concerns, she adds.

Another challenge with implementing this therapy into practice has been financial. Physicians are still unsure how much each product is going to cost, who will reimburse it, and who will be eligible to receive reimbursement. Those questions will need to be addressed before research is taken any further, as they play an important role in the accessibility and the applicability of this therapy, concludes Shah.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,